CN104173629A - Anti-lumbago tablet and preparation method thereof - Google Patents
Anti-lumbago tablet and preparation method thereof Download PDFInfo
- Publication number
- CN104173629A CN104173629A CN201410402631.6A CN201410402631A CN104173629A CN 104173629 A CN104173629 A CN 104173629A CN 201410402631 A CN201410402631 A CN 201410402631A CN 104173629 A CN104173629 A CN 104173629A
- Authority
- CN
- China
- Prior art keywords
- dry
- lumbago
- rhizoma
- carbon dioxide
- ground
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an anti-lumbago tablet and a preparation method thereof. The preparation method is characterized by comprising the following steps: extracting 81g of nutmeg, 81g of herba eupatorii, 108g of angelica, 81g of atractylodes macrocephala, 81g of radix achyranthis bidentatae, 27g of cinnamon, 27g of frankincense, 81g of rhizoma cibotii, 43g of root of common peony and 54g of rhizoma alismatis by adopting a CO2 supercritical extraction method, drying under reduced pressure, grinding into a nano dry paste by using a high-energy nano impact mill, and adding functional auxiliary materials to prepare the anti-lumbago tablet. According to the anti-lumbago tablet, the disintegration time is remarkably shortened, the treatment effect is remarkably superior to that of commercially available anti-lumbago tablets, and the positive effect is achieved.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of anti-lumbago tablet and preparation method thereof.
Background technology
Anti-lumbago tablet has strengthening vital energy of kidney, promoting blood circulation and stopping pain effect.For lumbago due to renal deficiency, lumbar muscle strain.Commercially available anti-lumbago tablet is due to prescription and technological reason, and curative effect is not satisfactory, and preparation adopts traditional handicraft preparation, has the deficiencies such as prolonged disintegration, curative effect are low.
Summary of the invention
The present invention, for overcoming above-mentioned deficiency, provides anti-lumbago tablet that a kind of disintegration rate is fast, curative effect is high and preparation method thereof.
Invention embodiment is as follows:
Get Semen Myristicae 81g, Herba Eupatorii 81g, Radix Angelicae Sinensis 108g, Rhizoma Atractylodis Macrocephalae 81g, Radix Achyranthis Bidentatae 81g, Cortex Cinnamomi 27g, Olibanum 27g, Rhizoma Cibotii 81g, Radix Paeoniae Rubra 43g, Rhizoma Alismatis 54g, be ground into 60 order coarse powder, adopt carbon dioxide supercritical extraction method to extract, extracting pressure 20～40Mpa, 20～40 ℃ of extraction temperature, separator pressure 10～20Mpa, 40～60 ℃ of separator temperatures, disengaging time 2～4 hours, carbon dioxide flow 20～40L per hour, obtains extracting solution; Get 60 ℃～80 ℃ drying under reduced pressure of extracting solution, get dry extract; Get dry cream and add L MALIC ACID 80～120g, adopt the impact grinding of high energy nanometer to be ground into the mixing dried cream powder of particle diameter 200～300nm; Get mixing dried cream powder, lactose 35～45g, crospolyvinylpyrrolidone 35～45g, cross-linking sodium carboxymethyl cellulose 35～45g, hypromellose 25～35g, micropowder silica gel 15～25g, mix homogeneously, with 50～70% ethanol wet granulations, 60 ℃～80 ℃ dry, additional carboxymethyl starch sodium 7～9g, magnesium stearate 1～3g, granulate, is pressed into 1000, makes anti-lumbago tablet.
The raw material standards that above-mentioned embodiment is mentioned is as follows:
Semen Myristicae: Chinese Pharmacopoeia version one ministerial standard in 2005.This product has another name called Fructus Amomi Rotundus, flesh fruit, semen myristicae.For myristicaceae plant Semen Myristicae
The kernel of Myristica fragrans Houtt.Main product is in states such as Malaysia, Indonesia, Sri Lanka, and extensively cultivate torrid areas.There is introducing and planting on the ground such as China Taiwan, Guangdong, Yunnan.Pluck mature fruit summer, remove peel, peel off aril, low temperature is slowly dried.
Herba Eupatorii: Chinese Pharmacopoeia version one ministerial standard in 2005.This product is the dry aerial parts of feverfew Herba Eupatorii Eupatorium fortunei Turcz..Summer, Qiu Erji tap at twice, remove impurity, dry.
Radix Angelicae Sinensis: Chinese Pharmacopoeia version one ministerial standard in 2005.This product is umbelliferae angelica Angelica sinensis(Oliv.) dry root of Diels.Autumn end excavates, and removes fibrous root and silt, after moisture slightly evaporates, is bundled into wisp, and upper canopy, with pyrotechnics smoke-dried beancurd slowly.
The Rhizoma Atractylodis Macrocephalae: Chinese Pharmacopoeia version one ministerial standard in 2005.This product is the dry rhizome of feverfew Rhizoma Atractylodis Macrocephalae Atractylodes macrocephala Koldz..When withered and yellow, the upper leaf of bottom leaf in winter becomes fragile, excavate, remove silt, dry or dry, then remove fibrous root.
Radix Achyranthis Bidentatae: Chinese Pharmacopoeia version one ministerial standard in 2005.This product is the dry root of amaranthaceous plant Radix Achyranthis Bidentatae Achyranthes bidentata Bl..Excavate when stem and leaf is withered winter, removes fibrous root and silt, is bundled into wisp, shines as for after wrinkle, and top is trimmed, and dries.
Cortex Cinnamomi: Chinese Pharmacopoeia version one ministerial standard in 2005.This product is the dry bark of canella Cortex Cinnamomi CiNNamomum cassia Presl.More than stripping autumn, dry in the shade.
Olibanum: Chinese Pharmacopoeia version one ministerial standard in 2005.Real name smokes land, and the smoked Lu Xiang of another name, horse hair is fragrant, nipple is fragrant, the perfume (or spice) that collapses, it pool is fragrant, Moller is fragrant, many gals Luo Xiang etc., and Latin literary fame Boswellia carteri. is the cured resin of Burseraceae aiphyllium.Because it drips into mamillary, therefore also claim nipple fragrant.
Rhizoma Cibotii: Chinese Pharmacopoeia version one ministerial standard in 2005.This product is Dicksoniaceae plant Rhizoma Cibotii Cibotium barometz(L.) dry rhizome of J.Sm..Autumn, two seasons of winter excavate, and remove silt. and dry; Or remove hard root, petiole and golden yellow fine hair, and cut sheet, dry, be " raw Rhizoma Cibotii sheet "; After steaming, shine to six, seventy percent dry, cut sheet, dry, be " ripe Rhizoma Cibotii sheet ".
Radix Paeoniae Rubra: Chinese Pharmacopoeia version one ministerial standard in 2005.This product is the dry root of ranunculaceae plant Radix Paeoniae Paeonia lactiflora Pall. or river Radix Paeoniae Rubra Paeonia veitchii Lynch.Spring, Qiu Erji excavate, and remove rhizome, fibrous root and silt, dry.
Rhizoma Alismatis: Chinese Pharmacopoeia version one ministerial standard in 2005.This product is Notes On Alism At Aceae Rhizoma Alismatis Alisma orientalis(Sam.) dry tuber of Juzep..Excavate when stem and leaf starts to wither winter, and cleaning, drying, remove fibrous root and rough bark.
L MALIC ACID: Chinese Pharmacopoeia version two ministerial standards in 2010.
Lactose: Chinese Pharmacopoeia version two ministerial standards in 2010.
Crospolyvinylpyrrolidone: Chinese Pharmacopoeia version two ministerial standards in 2010.
Cross-linking sodium carboxymethyl cellulose: Chinese Pharmacopoeia version two ministerial standards in 2010.
Hypromellose: Chinese Pharmacopoeia version two ministerial standards in 2010.
Micropowder silica gel: Chinese Pharmacopoeia version two ministerial standards in 2010.
Carboxymethylstach sodium: Chinese Pharmacopoeia version two ministerial standards in 2010.
Magnesium stearate: Chinese Pharmacopoeia version two ministerial standards in 2010.
Above anti-lumbago tablet raw material Jun Kecong used pharmaceuticals buys and obtains, as long as meet national standard, all can be used to implement the present invention program.
In foregoing invention scheme, term used is pharmacy proprietary term, as " decompression " etc. all defers to Chinese Pharmacopoeia regulation and the pharmacy standard of being correlated with.
The g of unit in the present invention can be also other weight portion, does not affect the present invention program's enforcement.
Equipment Market described in the present invention program all has sale, is not limited to typical production producer, as long as technical specification can reach requirement, all can be used to realize the present invention.
Four specific embodiment
Specific embodiments of the invention 1
Get Semen Myristicae 81g, Herba Eupatorii 81g, Radix Angelicae Sinensis 108g, Rhizoma Atractylodis Macrocephalae 81g, Radix Achyranthis Bidentatae 81g, Cortex Cinnamomi 27g, Olibanum 27g, Rhizoma Cibotii 81g, Radix Paeoniae Rubra 43g, Rhizoma Alismatis 54g, be ground into 60 order coarse powder, adopt carbon dioxide supercritical extraction method to extract, extracting pressure 20Mpa, 20 ℃ of extraction temperature, separator pressure 10Mpa, 40 ℃ of separator temperatures, disengaging time 2 hours, carbon dioxide flow 20L per hour, obtains extracting solution; Get 60 ℃ of drying under reduced pressure of extracting solution, get dry extract; Get dry cream and add L MALIC ACID 80g, adopt the impact grinding of high energy nanometer to be ground into the mixing dried cream powder of particle diameter 200～300nm; Get mixing dried cream powder, lactose 35g, crospolyvinylpyrrolidone 35g, cross-linking sodium carboxymethyl cellulose 35g, hypromellose 25g, micropowder silica gel 15g, mix homogeneously, with 50% ethanol wet granulation, 60 ℃ dry, additional carboxymethyl starch sodium 7g, magnesium stearate 1g, granulate, is pressed into 1000, makes anti-lumbago tablet.
Specific embodiments of the invention 2
Get Semen Myristicae 81g, Herba Eupatorii 81g, Radix Angelicae Sinensis 108g, Rhizoma Atractylodis Macrocephalae 81g, Radix Achyranthis Bidentatae 81g, Cortex Cinnamomi 27g, Olibanum 27g, Rhizoma Cibotii 81g, Radix Paeoniae Rubra 43g, Rhizoma Alismatis 54g, be ground into 60 order coarse powder, adopt carbon dioxide supercritical extraction method to extract, extracting pressure 40Mpa, 40 ℃ of extraction temperature, separator pressure 20Mpa, 60 ℃ of separator temperatures, disengaging time 4 hours, carbon dioxide flow 40L per hour, obtains extracting solution; Get 80 ℃ of drying under reduced pressure of extracting solution, get dry extract; Get dry cream and add L MALIC ACID 120g, adopt the impact grinding of high energy nanometer to be ground into the mixing dried cream powder of particle diameter 200～300nm; Get mixing dried cream powder, lactose 45g, crospolyvinylpyrrolidone 45g, cross-linking sodium carboxymethyl cellulose 45g, hypromellose 35g, micropowder silica gel 25g, mix homogeneously, with 70% ethanol wet granulation, 80 ℃ dry, additional carboxymethyl starch sodium 9g, magnesium stearate 3g, granulate, is pressed into 1000, makes anti-lumbago tablet.
Specific embodiments of the invention 3
Get Semen Myristicae 81g, Herba Eupatorii 81g, Radix Angelicae Sinensis 108g, Rhizoma Atractylodis Macrocephalae 81g, Radix Achyranthis Bidentatae 81g, Cortex Cinnamomi 27g, Olibanum 27g, Rhizoma Cibotii 81g, Radix Paeoniae Rubra 43g, Rhizoma Alismatis 54g, be ground into 60 order coarse powder, adopt carbon dioxide supercritical extraction method to extract, extracting pressure 30Mpa, 30 ℃ of extraction temperature, separator pressure 15Mpa, 50 ℃ of separator temperatures, disengaging time 3 hours, carbon dioxide flow 30L per hour, obtains extracting solution; Get 70 ℃ of drying under reduced pressure of extracting solution, get dry extract; Get dry cream and add L MALIC ACID 100g, adopt the impact grinding of high energy nanometer to be ground into the mixing dried cream powder of particle diameter 200～300nm; Get mixing dried cream powder, lactose 40g, crospolyvinylpyrrolidone 40g, cross-linking sodium carboxymethyl cellulose 40g, hypromellose 30g, micropowder silica gel 20g, mix homogeneously, with 60% ethanol wet granulation, 70 ℃ dry, additional carboxymethyl starch sodium 8g, magnesium stearate 2g, granulate, is pressed into 1000, makes anti-lumbago tablet.
Above embodiment explanation, adopts extreme condition and the optimal conditions of embodiment of the present invention all can make anti-lumbago tablet.The anti-lumbago tablet making with embodiment 3 is below investigated actual effect of the present invention:
(1) embodiment 3 anti-lumbago tablets and contrast disintegration of commercially available anti-lumbago tablet
1 disintegration time mensuration method
Pressing Chinese Pharmacopoeia version appendix XII A in 2010 measures.
Contrast 2 disintegrations
Table 1 embodiment 3 anti-lumbago tablets and commercially available anti-lumbago tablet contrast table disintegration
The above results shows, anti-lumbago tablet prepared by the present invention has the remarkable advantages such as disintegration rate is fast, bioavailability is high with respect to commercially available anti-lumbago tablet.
(2) embodiment 3 anti-lumbago tablets and commercially available anti-lumbago tablet treatment lumbago due to renal deficiency, lumbar muscle strain disease clinical observation on the therapeutic effect
1 case situation
Statistics outpatient service and inpatient, observe lumbago due to renal deficiency, lumbar muscle strain disease case 100 examples, 50 years old mean age altogether.Patient is divided into two groups, and test group is taken embodiment 3 anti-lumbago tablets, and matched group is taken commercially available anti-lumbago tablet.
2 efficacy assessment standards
According to new Chinese medicine, treat the guideline of clinical investigations tcm syndrome curative effect determinate standard of suffering from a deficiency of the kidney:
Clinical recovery: tcm clinical practice symptom, sign disappear or substantially disappear, and syndrome integration reduces >=95%.
Effective: tcm clinical practice symptom, sign are obviously improved, syndrome integration reduces >=70%.
Effective: tcm clinical practice symptom, sign all take a favorable turn, syndrome integration reduces >=30%.
Invalid: tcm clinical practice symptom, sign are all not improved or increase the weight of, syndrome integration reduces < 30%.
Computing formula: [integration before (the rear integration of integration-treatment before treatment) ÷ treatment] * 100%.
3 clinical observation result
Table 2 embodiment 3 anti-lumbago tablets and commercially available anti-lumbago tablet clinical efficacy contrast table
Above-mentioned clinical observation on the therapeutic effect result shows, anti-lumbago tablet prepared by the present invention is in treatment lumbago due to renal deficiency, during lumbar muscle strain disease, evident in efficacy higher than commercially available anti-lumbago tablet, p < 0.05.
Claims (3)
1. a Chinese medicine for the treatment of lumbago due to renal deficiency, lumbar muscle strain disease, it is characterized in that getting Semen Myristicae 81g, Herba Eupatorii 81g, Radix Angelicae Sinensis 108g, Rhizoma Atractylodis Macrocephalae 81g, Radix Achyranthis Bidentatae 81g, Cortex Cinnamomi 27g, Olibanum 27g, Rhizoma Cibotii 81g, Radix Paeoniae Rubra 43g, Rhizoma Alismatis 54g, is ground into 60 order coarse powder, employing carbon dioxide supercritical extraction method is extracted, extracting pressure 20～40Mpa, 20～40 ℃ of extraction temperature, separator pressure 10～20Mpa, 40～60 ℃ of separator temperatures, disengaging time 2～4 hours, carbon dioxide flow 20～40L per hour, obtains extracting solution; Get 60 ℃～80 ℃ drying under reduced pressure of extracting solution, get dry extract; Get dry cream and add L MALIC ACID 80～120g, adopt the impact grinding of high energy nanometer to be ground into the mixing dried cream powder of particle diameter 200～300nm; Get mixing dried cream powder, lactose 35～45g, crospolyvinylpyrrolidone 35～45g, cross-linking sodium carboxymethyl cellulose 35～45g, hypromellose 25～35g, micropowder silica gel 15～25g, mix homogeneously, with 50～70% ethanol wet granulations, 60 ℃～80 ℃ dry, additional carboxymethyl starch sodium 7～9g, magnesium stearate 1～3g, granulate, makes anti-lumbago tablet.
2. the preparation method of Chinese medicine according to claim 1, it is characterized in that getting Semen Myristicae 81g, Herba Eupatorii 81g, Radix Angelicae Sinensis 108g, Rhizoma Atractylodis Macrocephalae 81g, Radix Achyranthis Bidentatae 81g, Cortex Cinnamomi 27g, Olibanum 27g, Rhizoma Cibotii 81g, Radix Paeoniae Rubra 43g, Rhizoma Alismatis 54g, is ground into 60 order coarse powder, employing carbon dioxide supercritical extraction method is extracted, extracting pressure 20～40Mpa, 20～40 ℃ of extraction temperature, separator pressure 10～20Mpa, 40～60 ℃ of separator temperatures, disengaging time 2～4 hours, carbon dioxide flow 20～40L per hour, obtains extracting solution; Get 60 ℃～80 ℃ drying under reduced pressure of extracting solution, get dry extract; Get dry cream and add L MALIC ACID 80～120g, adopt the impact grinding of high energy nanometer to be ground into the mixing dried cream powder of particle diameter 200～300nm; Get mixing dried cream powder, lactose 35～45g, crospolyvinylpyrrolidone 35～45g, cross-linking sodium carboxymethyl cellulose 35～45g, hypromellose 25～35g, micropowder silica gel 15～25g, mix homogeneously, with 50～70% ethanol wet granulations, 60 ℃～80 ℃ dry, additional carboxymethyl starch sodium 7～9g, magnesium stearate 1～3g, granulate, makes anti-lumbago tablet.
3. the preparation method of Chinese medicine according to claim 1, gets Semen Myristicae 81g, Herba Eupatorii 81g, Radix Angelicae Sinensis 108g, Rhizoma Atractylodis Macrocephalae 81g, Radix Achyranthis Bidentatae 81g, Cortex Cinnamomi 27g, Olibanum 27g, Rhizoma Cibotii 81g, Radix Paeoniae Rubra 43g, Rhizoma Alismatis 54g, be ground into 60 order coarse powder, adopt carbon dioxide supercritical extraction method to extract, extracting pressure 30Mpa, 30 ℃ of extraction temperature, separator pressure 15Mpa, 50 ℃ of separator temperatures, disengaging time 3 hours, carbon dioxide flow 30L per hour, obtains extracting solution; Get 70 ℃ of drying under reduced pressure of extracting solution, get dry extract; Get dry cream and add L MALIC ACID 100g, adopt the impact grinding of high energy nanometer to be ground into the mixing dried cream powder of particle diameter 200～300nm; Get mixing dried cream powder, lactose 40g, crospolyvinylpyrrolidone 40g, cross-linking sodium carboxymethyl cellulose 40g, hypromellose 30g, micropowder silica gel 20g, mix homogeneously, with 60% ethanol wet granulation, 70 ℃ dry, additional carboxymethyl starch sodium 8g, magnesium stearate 2g, granulate, is pressed into 1000, makes anti-lumbago tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410402631.6A CN104173629A (en) | 2014-08-16 | 2014-08-16 | Anti-lumbago tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410402631.6A CN104173629A (en) | 2014-08-16 | 2014-08-16 | Anti-lumbago tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104173629A true CN104173629A (en) | 2014-12-03 |
Family
ID=51955153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410402631.6A Pending CN104173629A (en) | 2014-08-16 | 2014-08-16 | Anti-lumbago tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104173629A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102600234A (en) * | 2012-04-13 | 2012-07-25 | 孙长海 | Swertia mileensis dispersible tablet and preparation method thereof |
| CN103028005A (en) * | 2012-10-08 | 2013-04-10 | 卞毓平 | Preparation method of anti-lumbago tablet and application thereof |
-
2014
- 2014-08-16 CN CN201410402631.6A patent/CN104173629A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102600234A (en) * | 2012-04-13 | 2012-07-25 | 孙长海 | Swertia mileensis dispersible tablet and preparation method thereof |
| CN103028005A (en) * | 2012-10-08 | 2013-04-10 | 卞毓平 | Preparation method of anti-lumbago tablet and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104173629A (en) | Anti-lumbago tablet and preparation method thereof | |
| CN104116840A (en) | Fukang tablets and preparation method thereof | |
| CN105726812A (en) | Anti-lumbago tablets and preparation method thereof | |
| CN104383037A (en) | Anti-cerebral-thrombosis tablets and preparation method thereof | |
| CN104127828A (en) | Guangmaining tablet and preparation method thereof | |
| CN104474384A (en) | Fuganning tablet and preparation method thereof | |
| CN104491282A (en) | Muscle-relaxing and blood-activating tablet and preparation method thereof | |
| CN104224945A (en) | Hepatitis B body-resistance-strengthening capsule and preparation method thereof | |
| CN105395514A (en) | Zhonghua ganling capsule and preparation method thereof | |
| CN104225046A (en) | Hyperostosis-resistant tablet and preparation method thereof | |
| CN104225359A (en) | Jiangtangjia tablet and preparation method thereof | |
| CN105456700A (en) | Kidney-tonifying bone-supplementing capsule and preparation method thereof | |
| CN104383059A (en) | Compound berberine tablet and method for preparing same | |
| CN104116797B (en) | A kind of Jingzhi Guanxin tablet and preparation method thereof | |
| CN104224956A (en) | Mind-calming tablet and preparation method thereof | |
| CN104435211A (en) | Tablet for treating emphysema and method for preparing tablet for treating emphysema | |
| CN104435112A (en) | Soothing pill and preparation method thereof | |
| CN104127674A (en) | Mind-relief tablet and preparation method thereof | |
| CN105687685A (en) | Mind relieving tablet and preparation method thereof | |
| CN105362578A (en) | Tablets for regulating menstruation and preparation method thereof | |
| CN105362393A (en) | Fengtongning tablet and preparation method thereof | |
| CN105770584A (en) | Heart calming tablet and preparation method thereof | |
| CN105362948A (en) | Tablets for treating traumatic injuries and preparation method thereof | |
| CN105343677A (en) | Embolism eliminating and collateral dredging capsules and preparing method thereof | |
| CN105412753A (en) | Stone removing capsule and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20141203 |